TORONTO, Oct. 15, 2015 /CNW/ - The Federal Court of Canada ruled in favour of Apotex, quashing the Import Ban announced by Health Canada on September 30, 2014. The Ban had restricted importation of drug products from facilities in India, including two facilities operated by Apotex.
In quashing the Ban, the Honourable Justice Michael D. Manson concluded that the Minister acted improperly and unfairly; and was motivated by an improper purpose. Justice Manson therefore ruled that the Ban be quashed.
In addition to overturning the Ban, the Court directed that public statements relating to the Ban issued by the Minister and her delegates at Health Canada on September 30, 2014, be retracted.
"Apotex is pleased with the vindication that this decision provides," said Apotex CEO & President Dr. Jeremy Desai. "Apotex always has been and remains a most trusted partner in the global healthcare community. Apotex is fully dedicated to producing highest quality, safe, and efficacious medicines for all of our global consumers."
Founded in 1974, Apotex has grown to over 6,000 employees in Canada and over 10,000 employees worldwide with exports to 115 countries. Apotex is the largest R&D company in the pharmaceutical industry with planned expenditures of $2 billion over the next 10 years.
SOURCE Apotex Inc.
Image with caption: "Apotex Inc. (CNW Group/Apotex Inc.)". Image available at: http://photos.newswire.ca/images/download/20151015_C4780_PHOTO_EN_522162.jpg
For further information: Mr. Elie Betito, Director of Government Relations, Tel: 416-749-9300 Ext. 7366, Cell: 416-558-5491